Cargando…
Antithyroid drugs in Graves’ disease: Are we stretching it too far?
INTRODUCTION: Early and durable achievement of euthyroid or hypothyroid status with low likelihood of relapse is the key to effective treatment of Graves’ disease (GD). Although antithyroid drugs (ATDs) are commonly used first-line agents, likelihood of remission remains highest with radioactive iod...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5040037/ https://www.ncbi.nlm.nih.gov/pubmed/27730067 http://dx.doi.org/10.4103/2230-8210.190525 |
_version_ | 1782456175165440000 |
---|---|
author | Jayaraman, Muthukrishnan Pawah, Anil Kumar Narayanan, C. S. |
author_facet | Jayaraman, Muthukrishnan Pawah, Anil Kumar Narayanan, C. S. |
author_sort | Jayaraman, Muthukrishnan |
collection | PubMed |
description | INTRODUCTION: Early and durable achievement of euthyroid or hypothyroid status with low likelihood of relapse is the key to effective treatment of Graves’ disease (GD). Although antithyroid drugs (ATDs) are commonly used first-line agents, likelihood of remission remains highest with radioactive iodine (RAI) therapy and surgery. Data regarding efficacy and economical superiority of RAI therapy over ATDs are lacking from India. This study was designed to study the response to long-term (>12 months) use of ATDs in GD with respect to attainment of remission and to compare the cost of treatment with ATDs versus RAI therapy beyond 12 months. SETTINGS: The study was conducted in a tertiary care center. STUDY DESIGN: This was a retrospective analysis. MATERIALS AND METHODS: Patients of GD in our follow-up from February 2009 to March 2016 who had received ATDs for a duration exceeding 12 months were retrospectively analyzed. Patients who underwent radioablation after a period of at least 12 months on ATDs were analyzed and their status was recorded after a minimum of 6 months after radioablation. Patients who remained hyperthyroid beyond 12 months and received RAI therapy were further compared with those who continued on ATDs, for achievement of euthyroid or hypothyroid status. Cost analysis was done for follow-ups and treatment and compared. STATISTICAL ANALYSIS USED: All analyses were done using Fisher's exact test for categorical and descriptive statistics for numerical data. RESULTS: Use of ATDs leading to euthyroid and hypothyroid status in GD patients was only significant beyond 24 years when compared to those at <12–18 months therapy (P = 0.0262 and P = 0.0217, respectively). The patients who ended up with hypothyroid status were significantly greater in RAI group compared to ATD group (P = 0.0003). Cost of therapy per patient beyond 12 months was lower in the RAI group compared to the ATD group (cost difference Rs. 5435.00). CONCLUSIONS: Within limitations, our study demonstrates that RAI is effective and economical option in GD. |
format | Online Article Text |
id | pubmed-5040037 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-50400372016-10-11 Antithyroid drugs in Graves’ disease: Are we stretching it too far? Jayaraman, Muthukrishnan Pawah, Anil Kumar Narayanan, C. S. Indian J Endocrinol Metab Original Article INTRODUCTION: Early and durable achievement of euthyroid or hypothyroid status with low likelihood of relapse is the key to effective treatment of Graves’ disease (GD). Although antithyroid drugs (ATDs) are commonly used first-line agents, likelihood of remission remains highest with radioactive iodine (RAI) therapy and surgery. Data regarding efficacy and economical superiority of RAI therapy over ATDs are lacking from India. This study was designed to study the response to long-term (>12 months) use of ATDs in GD with respect to attainment of remission and to compare the cost of treatment with ATDs versus RAI therapy beyond 12 months. SETTINGS: The study was conducted in a tertiary care center. STUDY DESIGN: This was a retrospective analysis. MATERIALS AND METHODS: Patients of GD in our follow-up from February 2009 to March 2016 who had received ATDs for a duration exceeding 12 months were retrospectively analyzed. Patients who underwent radioablation after a period of at least 12 months on ATDs were analyzed and their status was recorded after a minimum of 6 months after radioablation. Patients who remained hyperthyroid beyond 12 months and received RAI therapy were further compared with those who continued on ATDs, for achievement of euthyroid or hypothyroid status. Cost analysis was done for follow-ups and treatment and compared. STATISTICAL ANALYSIS USED: All analyses were done using Fisher's exact test for categorical and descriptive statistics for numerical data. RESULTS: Use of ATDs leading to euthyroid and hypothyroid status in GD patients was only significant beyond 24 years when compared to those at <12–18 months therapy (P = 0.0262 and P = 0.0217, respectively). The patients who ended up with hypothyroid status were significantly greater in RAI group compared to ATD group (P = 0.0003). Cost of therapy per patient beyond 12 months was lower in the RAI group compared to the ATD group (cost difference Rs. 5435.00). CONCLUSIONS: Within limitations, our study demonstrates that RAI is effective and economical option in GD. Medknow Publications & Media Pvt Ltd 2016 /pmc/articles/PMC5040037/ /pubmed/27730067 http://dx.doi.org/10.4103/2230-8210.190525 Text en Copyright: © Indian Journal of Endocrinology and Metabolism http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Jayaraman, Muthukrishnan Pawah, Anil Kumar Narayanan, C. S. Antithyroid drugs in Graves’ disease: Are we stretching it too far? |
title | Antithyroid drugs in Graves’ disease: Are we stretching it too far? |
title_full | Antithyroid drugs in Graves’ disease: Are we stretching it too far? |
title_fullStr | Antithyroid drugs in Graves’ disease: Are we stretching it too far? |
title_full_unstemmed | Antithyroid drugs in Graves’ disease: Are we stretching it too far? |
title_short | Antithyroid drugs in Graves’ disease: Are we stretching it too far? |
title_sort | antithyroid drugs in graves’ disease: are we stretching it too far? |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5040037/ https://www.ncbi.nlm.nih.gov/pubmed/27730067 http://dx.doi.org/10.4103/2230-8210.190525 |
work_keys_str_mv | AT jayaramanmuthukrishnan antithyroiddrugsingravesdiseasearewestretchingittoofar AT pawahanilkumar antithyroiddrugsingravesdiseasearewestretchingittoofar AT narayanancs antithyroiddrugsingravesdiseasearewestretchingittoofar |